US 8501713
Drug combinations for the treatment of duchenne muscular dystrophy
granted A61KA61K31/423A61K31/573
Quick answer
US patent 8501713 (Drug combinations for the treatment of duchenne muscular dystrophy) held by Summit Corporation Plc expires Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Summit Corporation Plc
- Grant date
- Tue Aug 06 2013 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Aug 01 2033 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/423, A61K31/573, A61K45/06, A61P